Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer. - Wikidata - wikimedia - TriplyDB

Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer.

Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer.

http://www.wikidata.org/entity/Q35166338

about

Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation.Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas Breast conservation therapy after neoadjuvant chemotherapy: optimization of a multimodality approach.Surgical treatment of primary breast cancer in the neoadjuvant setting.MRI and ultrasound evaluation of invasive lobular carcinoma of the breast after primary systemic therapy.Neoadjuvant chemotherapy increases the rate of breast conservation in lobular-type breast cancer patients.Surgical Management of Breast Cancer Treated with Neoadjuvant Therapy

P2860

Q34961321-72BAFBCA-35A2-458F-9F40-6F48A1C22BAC Q36594068-562B21C7-0300-4157-8E51-EA8A81418996 Q38195542-FA22BC25-840B-4F04-99F9-3EE4708D917C Q38212607-6493D919-A3E9-4878-817C-09DC04302096 Q43471412-CB9242B3-4A06-4D8D-B6A9-8C54C42C2355 Q51021864-CBBFACA1-A510-4BD9-818B-A813990E2A56 Q57495769-0B9AC72E-B854-4870-A206-5973D0E43379

P2860

Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer.

http://www.wikidata.org/entity/Q35166338

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer.

@ast

Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer.

@en

type

label

Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer.

@ast

Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer.

@en

prefLabel

Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer.

@ast

Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer.

@en

P1433

Q35166338-BA13B29A-6033-40CD-834E-705E0AE4B676

P1476

Q35166338-EF95ED73-6646-41A2-9D0C-E5346BCB4FED

P2093

Q35166338-29CD6489-4A19-48D1-9A4C-C38C062ED6CE

Q35166338-59EA9F4F-DF27-4F8C-8E3B-B5F9C24FFFEB

Q35166338-60159C2E-3699-4125-A82C-19BF314D140D

Q35166338-8C21C973-6FE5-4130-A574-18423DB45C5F

Q35166338-959E5892-1FF0-4A12-A968-13498FA2E3DD

Q35166338-C10D8CE3-B217-4866-A50B-2B1656F3976F

Q35166338-CF1E1A45-02D3-47F8-B500-A14B8865540A

Q35166338-F5FCD2D2-8D52-4D1B-B3C4-525C0581D8C9

Q35166338-F7AA5A6D-152A-4F35-8423-008C3E84F227

P2860

Q35166338-0BEB20D5-DB1C-4F2A-8E71-169CAADF0CD6

Q35166338-108D88A2-2744-4B21-BAE4-15B44584FE01

Q35166338-2D9212E5-7CFB-4B12-85F6-7A6E3EDD7563

Q35166338-4858293D-4CA7-42D8-8C99-FDBDD94DC2DB

Q35166338-4B622F2A-8AE5-4483-A99C-04890225328C

Q35166338-5930040B-C1CD-4A7A-9609-FE720F870E44

Q35166338-6A858CAC-9B14-4639-8D9A-60F9E6290402

Q35166338-7DE7D4DB-8D49-49E8-89FD-BA2D8B60E5A1

Q35166338-D7A84419-55BD-4B74-8C45-8EDDC81D81BB

Q35166338-FBF50138-2653-451F-A606-84D0C1CEE3F2

P304

Q35166338-A235A621-82AF-4573-BBFE-2C626768D762

P31

Q35166338-11A78F73-5443-4B7A-ABEC-F1E166831667

P356

Q35166338-E4F32A79-BDDF-431E-BBA7-DF7CA2C7B9B5

P407

Q35166338-F1ADDBA5-EBE2-4E73-9AD4-8754ED337311

P433

Q35166338-D22D9773-ACF7-4075-BAD1-A32E18E144D9

P478

Q35166338-A6D95917-53ED-48AD-906E-9CB62E07C522

P50

Q35166338-EB1C1FEB-B6D8-4B0A-8934-6321D79FD3D3

P577

Q35166338-7661000F-874D-47E4-91F6-02899B6414B0

P698

Q35166338-10C7AB62-7291-4254-A873-88A3CCEE44FF

P921

Q35166338-4A54F72A-3AA0-4A5B-B48B-FDB4D61A3043

P932

Q35166338-E3557169-E769-4BED-A500-77E348334625

P356

J.AMJSURG.2009.01.006

P1433

The American Journal of Surgery

P1476

Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer.

@en

P2093

Betsy Garrett

http://www.w3.org/2001/XMLSchema#string

Eva Singletary

http://www.w3.org/2001/XMLSchema#string

Gildy Babiera

http://www.w3.org/2001/XMLSchema#string

Henry Kuerer

http://www.w3.org/2001/XMLSchema#string

Isabelle Bedrosian

http://www.w3.org/2001/XMLSchema#string

Jamie Wagner

http://www.w3.org/2001/XMLSchema#string

Judy C Boughey

http://www.w3.org/2001/XMLSchema#string

Kelly K Hunt

http://www.w3.org/2001/XMLSchema#string

Lavinia P Middleton

http://www.w3.org/2001/XMLSchema#string

P2860

Association of infiltrating lobular carcinoma with positive surgical margins after breast-conservation therapy

Treatment trends in early-stage invasive lobular carcinoma: a report from the National Cancer Data Base.

The influence of infiltrating lobular carcinoma on the outcome of patients treated with breast-conserving surgery and radiation therapy.

Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma.

Presence of lobular carcinoma in situ does not increase local recurrence in patients treated with breast-conserving therapy.

Lobular carcinoma of the breast can be managed by breast-conserving therapy.

Role of conservation therapy for invasive lobular carcinoma of the breast.

Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma.

Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes.

Identifying patients at risk of compromised margins following breast conservation for lobular carcinoma.

P304

387-391

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.AMJSURG.2009.01.006

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

198

http://www.w3.org/2001/XMLSchema#string

P50

Funda Meric-Bernstam

P577

2009-04-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19362281

http://www.w3.org/2001/XMLSchema#string

P921

P932

4355914

http://www.w3.org/2001/XMLSchema#string